[
    [
        {
            "time": "",
            "original_text": "乐普医疗分拆全资子公司乐普诊断科创板IPO，疫情下业绩暴增难掩母公司销售渠道依赖隐忧",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "分拆",
                    "乐普诊断",
                    "科创板",
                    "IPO",
                    "疫情",
                    "业绩暴增",
                    "销售渠道依赖"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "乐普医疗分拆全资子公司乐普诊断科创板IPO，疫情下业绩暴增难掩母公司销售渠道依赖隐忧",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【浙商医药|周报】把握中国优势，就是把握明年行情",
            "features": {
                "keywords": [
                    "浙商医药",
                    "周报",
                    "中国优势",
                    "行情"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【浙商医药|周报】把握中国优势，就是把握明年行情",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "乐普医疗(300003.SZ)：氯沙坦钾氢氯噻嗪片通过药品一致性评价",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "氯沙坦钾氢氯噻嗪片",
                    "药品一致性评价"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "乐普医疗(300003.SZ)：氯沙坦钾氢氯噻嗪片通过药品一致性评价",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "浦江国际（2060.HK）: 估值处于历史低位，具备更大的修复潜能",
            "features": {
                "keywords": [
                    "浦江国际",
                    "估值",
                    "历史低位",
                    "修复潜能"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "浦江国际（2060.HK）: 估值处于历史低位，具备更大的修复潜能",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "近日药闻：乐普医疗子公司拟上市科创板，中国生物制药“纳尔复”过评",
            "features": {
                "keywords": [
                    "乐普医疗",
                    "子公司",
                    "科创板",
                    "中国生物制药",
                    "纳尔复",
                    "过评"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "近日药闻：乐普医疗子公司拟上市科创板，中国生物制药“纳尔复”过评",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 5,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "科创板IPO | 乐普医疗“送子赴考”，业绩“偶发性”增长后，乐普诊断路在何方?",
            "features": {
                "keywords": [
                    "科创板",
                    "IPO",
                    "乐普医疗",
                    "乐普诊断",
                    "业绩增长",
                    "偶发性"
                ],
                "sentiment_score": 0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "科创板IPO | 乐普医疗“送子赴考”，业绩“偶发性”增长后，乐普诊断路在何方?",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "【浙商医药|点评】器械创新方兴未艾，多领域孕育投资机会",
            "features": {
                "keywords": [
                    "浙商医药",
                    "器械创新",
                    "投资机会"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医疗器械"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【浙商医药|点评】器械创新方兴未艾，多领域孕育投资机会",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "【浙商医药|周报】如何选股？创新赋能、制造升级和降本增效",
            "features": {
                "keywords": [
                    "浙商医药",
                    "选股",
                    "创新赋能",
                    "制造升级",
                    "降本增效"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "【浙商医药|周报】如何选股？创新赋能、制造升级和降本增效",
                "Correlation": 4,
                "Sentiment": 7,
                "Importance": 5,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "",
            "original_text": "乐普诊断被分拆赴科创板上市净利润排同行尾部独立后能否“断奶”？",
            "features": {
                "keywords": [
                    "乐普诊断",
                    "分拆",
                    "科创板",
                    "净利润",
                    "同行尾部",
                    "断奶"
                ],
                "sentiment_score": 0.3,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "生物科技"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "乐普诊断被分拆赴科创板上市净利润排同行尾部独立后能否“断奶”？",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 10,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "29家公司高管出手增持动用资金1.09亿元",
            "features": {
                "keywords": [
                    "公司高管",
                    "增持",
                    "资金",
                    "1.09亿元"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "29家公司高管出手增持动用资金1.09亿元",
                "Correlation": 3,
                "Sentiment": 6,
                "Importance": 5,
                "Impact": 4,
                "Duration": 4,
                "Entity_Density": 1,
                "Market_Scope": 8,
                "Time_Proximity": 7,
                "Headline_Structure": 6,
                "Source_Recency": 7
            }
        }
    ]
]